Literature DB >> 20228223

Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits.

Yasushi Tomidokoro1, Agueda Rostagno, Thomas A Neubert, Yun Lu, G William Rebeck, Blas Frangione, Steven M Greenberg, Jorge Ghiso.   

Abstract

Mutations within the amyloid-beta (Abeta) sequence, especially those clustered at residues 21-23, which are linked to early onset familial Alzheimer's disease (AD), are primarily associated with cerebral amyloid angiopathy (CAA). The basis for this predominant vascular amyloid burden and the differential clinical phenotypes of cerebral hemorrhage/stroke in some patients and dementia in others remain unknown. The AbetaD23N Iowa mutation is associated with progressive AD-like dementia, often without clinically manifested intracerebral hemorrhage. Neuropathologically, the disease is characterized by predominant preamyloid deposits, severe CAA, and abundant neurofibrillary tangles in the presence of remarkably few mature plaques. Biochemical analyses using a combination of immunoprecipitation, mass spectrometry, amino acid sequence, and Western blot analysis performed after sequential tissue extractions to separately isolate soluble components, preamyloid, and fibrillar amyloid species indicated that the Iowa deposits are complex mixtures of mutated and nonmutated Abeta molecules. These molecules exhibited various degrees of solubility, were highly heterogeneous at both the N- and C-termini, and showed partial aspartate isomerization at positions 1, 7, and 23. This collection of Abeta species-the Iowa brain Abeta peptidome-contained clear imprints of amyloid clearance mechanisms yet highlighted the unique neuropathological features shared by a non-Abeta cerebral amyloidosis, familial Danish dementia, in which neurofibrillary tangles coexist with extensive pre-amyloid deposition in the virtual absence of fibrillar lesions. These data therefore challenge the importance of neuritic plaques as the sole contributors for the development of dementia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228223      PMCID: PMC2843474          DOI: 10.2353/ajpath.2010.090636

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  76 in total

Review 1.  Hereditary cerebral hemorrhage with amyloidosis--Dutch type (HCHWA-D): a review of the variety in phenotypic expression.

Authors:  M Bornebroek; J Haan; R A Roos
Journal:  Amyloid       Date:  1999-09       Impact factor: 7.141

2.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

Review 3.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.

Authors:  P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length.

Authors:  M P Murphy; L J Hickman; C B Eckman; S N Uljon; R Wang; T E Golde
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

Review 5.  The Sixth International Conference on Alzheimer's disease, Amsterdam, The Netherlands, July 1998. The amyloid cascade hypothesis debate: emerging consensus on the role of A beta and amyloid in Alzheimer's disease.

Authors:  D H Small
Journal:  Amyloid       Date:  1998-12       Impact factor: 7.141

6.  A stop-codon mutation in the BRI gene associated with familial British dementia.

Authors:  R Vidal; B Frangione; A Rostagno; S Mead; T Révész; G Plant; J Ghiso
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

7.  Analysis of transthyretin amyloid fibrils from vitreous samples in familial amyloidotic polyneuropathy (Val30Met).

Authors:  Y Ando; E Ando; P I Ohlsson; A Olofsson; O Sandgren; O Suhr; H Terazaki; K Obayashi; E Lundgren; M Ando; A Negi
Journal:  Amyloid       Date:  1999-06       Impact factor: 7.141

8.  Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40).

Authors:  J R Backstrom; G P Lim; M J Cullen; Z A Tökés
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

9.  Pathogenic amyloid beta-protein induces apoptosis in cultured human cerebrovascular smooth muscle cells.

Authors:  J Davis; D H Cribbs; C W Cotman; W E Van Nostrand
Journal:  Amyloid       Date:  1999-09       Impact factor: 7.141

10.  Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits.

Authors:  Y M Kuo; M R Emmerling; A S Woods; R J Cotter; A E Roher
Journal:  Biochem Biophys Res Commun       Date:  1997-08-08       Impact factor: 3.575

View more
  20 in total

Review 1.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid β and the Asn23 Iowa mutation.

Authors:  Silvia Fossati; Krysti Todd; Krystal Sotolongo; Jorge Ghiso; Agueda Rostagno
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

3.  Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.

Authors:  Erwin Cabrera; Paul Mathews; Emiliya Mezhericher; Thomas G Beach; Jingjing Deng; Thomas A Neubert; Agueda Rostagno; Jorge Ghiso
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-13       Impact factor: 5.187

Review 4.  The influence of the amyloid ß-protein and its precursor in modulating cerebral hemostasis.

Authors:  William E Van Nostrand
Journal:  Biochim Biophys Acta       Date:  2015-10-27

Review 5.  Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells.

Authors:  Jorge Ghiso; Silvia Fossati; Agueda Rostagno
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells.

Authors:  Mar Hernandez-Guillamon; Stephanie Mawhirt; Silvia Fossati; Steven Blais; Mireia Pares; Anna Penalba; Merce Boada; Pierre-Olivier Couraud; Thomas A Neubert; Joan Montaner; Jorge Ghiso; Agueda Rostagno
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

7.  Calpastatin modulates APP processing in the brains of β-amyloid depositing but not wild-type mice.

Authors:  Jose Morales-Corraliza; Jason D Berger; Matthew J Mazzella; Thomas A Neubert; Jorge Ghiso; Mala V Rao; Matthias Staufenbiel; Ralph A Nixon; Paul M Mathews
Journal:  Neurobiol Aging       Date:  2011-12-27       Impact factor: 4.673

Review 8.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

9.  Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9.

Authors:  Mar Hernandez-Guillamon; Stephanie Mawhirt; Steven Blais; Joan Montaner; Thomas A Neubert; Agueda Rostagno; Jorge Ghiso
Journal:  J Biol Chem       Date:  2015-04-20       Impact factor: 5.157

10.  Specific Binding of Cholesterol to C99 Domain of Amyloid Precursor Protein Depends Critically on Charge State of Protein.

Authors:  Afra Panahi; Asanga Bandara; George A Pantelopulos; Laura Dominguez; John E Straub
Journal:  J Phys Chem Lett       Date:  2016-08-26       Impact factor: 6.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.